Inicio>>Signaling Pathways>> Proteases>> Drug Metabolite>>Desmethyl Erlotinib

Desmethyl Erlotinib (Synonyms: CP 473,420, O-Desmethyl Erlotinib, OSI-420)

Catalog No.GC43419

Desmetil Erlotinib (OSI-420 base libre) es un metabolito activo de Erlotinib. Erlotinib es un potente inhibidor de la tirosina quinasa del EGFR.

Products are for research use only. Not for human use. We do not sell to patients.

Desmethyl Erlotinib Chemical Structure

Cas No.: 183321-86-0

Tamaño Precio Disponibilidad Cantidad
5 mg
123,00 $
Disponible
10 mg
214,00 $
Disponible
50 mg
612,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Desmethyl erlotinib is a metabolite of erlotinib . Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC50 = 2.5 µM). This inhibits tumor growth in human head and neck carcinoma HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg. Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 µM) and JAK2 mutant JAK2V617F positive hematopoietic progenitor cells (IC50 = 5 µM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia. Formulations containing erlotinib have been used to treat certain forms of cancer, including non-small cell lung cancer.

Reseñas

Review for Desmethyl Erlotinib

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Desmethyl Erlotinib

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.